Inspection Record

Wells Pharmacy Network LLC — FDA 483 Findings

US FDAInspected 2017-04-12Published 2024-01-17 6 findingsOther quality systemEquipment and facilityEnvironmental monitoringContamination controlAseptic processing and sterility assurance

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Non-depyrogenated containers were used in drug production.

2Equipment and facility

Buildings used in the processing of a drug products are not maintained in a good state of repair.

3Environmental monitoring

The use of the sporicidal agent in the cleanrooms is inadequate.

4Contamination control

Procedures designed to prevent microbiological contamination of drug products are not established, written, and followed.

5Aseptic processing and sterility assurance

Your firm failed to conduct smoke studies under dynamic conditions.

6Equipment and facility

The flow of drug products through the building is not designed to prevent contamination.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Wells Pharmacy Network LLC findings history — including this company's other documents US FDA documents, 2024 Go to Findings search